Q32 Bio Inc. — Director's Dealing 2023

Sep 8, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2023-09-06

Reporting Person: Seymour Albert (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-09-06	Common Stock	M	4620	—	Acquired	152322	Direct
2023-09-06	Common Stock	S	1448	$1.1502	Disposed	150874	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-09-06	Restricted Stock Units	$	M	4620	Disposed		Common Stock (4620)	Direct

Footnotes

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.

F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of RSUs.

F3: The RSUs will vest and settle as to one third of the RSUs on each of the first three anniversaries of September 6, 2022 so that such RSUs will become fully vested on September 6, 2025. The RSUs have no expiration date.